Company (symbol)

Date filed

Date comm.

Shares/Units (M)

Price

Shares out (M)

Lead, other underwriters

Gross (US$M)

Post-offering market cap (M)

Initial offerings total: $520.5M

Exagen Diagnostics Inc. (San Diego; XGN)1

9/18/19

9/20/19

3.6S

$14.00

11.49

Cowen; Cantor Fitzgerald; William Blair

$50.40

$160.86

IGM Biosciences Inc. (Mountain View, Calif.; IGMS)2

9/17/19

9/18/19

12.60S

$16.00

30.53

Jefferies; Piper Jaffray; Stifel; Guggenheim Securities

$201.30

$488.48

Satsuma Pharmaceuticals Inc. (South San Francisco; STSA)3

8/16/19

9/13/19

5.5S

$15.00

16.6

Credit Suisse; SVB Leerink; Evercore

$82.50

$249.00

Springworks Therapeutics Inc. (Stamford, Conn.; SWTX)4

8/16/19

9/13/19

10.35S

$18.00

43.23

J.P. Morgan; Goldman Sachs; Cowen; Wedbush Pacgrow

$186.30

$778.14

Number of IPOs in September: 4

Average value of September IPOs: $130.1M

Number of IPOs in 2019: 45

Total raised in IPOs in 2019: $6,624.66M

Average value of IPOs in 2019: $147.21M

Follow-on offerings total: $857.17M

Acadia Pharmaceuticals Inc. (San Diego; ACAD)5

11/26/18

9/17/19

6.25S

$40.00

150.7

BofA Merrill Lynch; J.P. Morgan; Cowen; SVB Leerink; Cantor; Canaccord Genuity; JMP Securities; Needham & Company

$250.00

$6,028.00

Bellus Health Inc. (Laval, Quebec; TSX:BLU)6

7/26/19

9/4/19

11.17S

$7.10

54.05

Jefferies; Cowen; Guggenheim Securities; Baird; Bloom Burton Securities

$79.37

$383.76

Bioxcel Therapeutics Inc. (New Haven, Conn.; BTAI)7

4/4/19

9/25/19

2.30S

$8.25

17.68

BMO Capital Markets; Thinkequity

$19.00

$145.86

Citius Pharmaceuticals Inc. (Cranford, N.J.; CTXR)8

9/25/19

9/25/19

7.82S and W for 7.82S

$0.89

29.89

H.C. Wainwright

$7.00

$26.60

Plus Therapeutics Inc. (Austin, Texas)9

9/26/19

9/26/19

3U

$5.00

3.44

H.C. Wainwright

$15.00

$17.20

Provention Bio Inc. (Oldwick, N.J.; PRVB)10

8/8/19

9/18/19

5.75S

$8.00

47.6

SVB Leerink; Cantor; H.C. Wainwright

$46.00

$380.80

PTC Therapeutics Inc. (South Plainfield, N.J.; PTCT)11

8/24/17

9/17/19

2.5S

$40.40

61.4

Credit Suisse

$100.00

$2,480.56

Translate Bio Inc. (Lexington, Mass.)12

7/19/19

9/18/19

9S

$10.00

60.1

Citigroup; Jefferies; SVB Leerink

$90.00

$601.00

Turning Point Therapeutics Inc. (San Diego; TPTX)13

9/3/19

9/5/19

4.5S

$45.00

35.79

Goldman Sachs; SVB Leerink; Guggenheim Securities; Wedbush Pacgrow

$202.50

$1,610.55

Vaxart Inc. (South San Francisco; VXRT)14

9/27/19

9/27/19

26.66S and W for 26.66S

$0.30

38.35

H.C. Wainwright; Arcadia Securities

$8.00

$11.51

VBI Vaccines Inc. (Cambridge, Mass.; VBIV)15

7/30/18

9/19/19

80.5S

$0.50

178.25

Raymond James; Oppenheimer; National Securities

$40.30

$89.13

Number of follow-ons in September: 11

Average value of September follow-ons: $77.92M

Number of follow-ons in 2019: 168

Total raised in follow-ons in 2019: $14,303.77M

Average value of follow-ons in 2019: $85.14M


Notes

Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biopharma companies that develop therapeutics.

HKEX = Hong Kong Stock Exchange.

1 Exagen Diagnostics' overallotment option: additional 540,000 shares.

2 Includes IGM Biosciences' overallotment option: additional 1.64 million shares.

3 Satsuma Pharmaceuticals' overallotment option: additional 825,000 shares.

4 Includes Springworks Therapeutics' overallotment option: additional 1.35M shares.

5 Acadia Pharmaceuticals' overallotment option: additional 937,500 shares.

6 Includes partial exercise of Bellus Health's overallotment option: 1.48M additional common shares.

7 Bioxcel Therapeutics' overallotment option: additional 345,454 shares.

8 Citius Pharmaceuticals' overallotment option: additional 1.17M shares.

9 Plus Therapeutics' overallotment option: additional 450,000 shares.

10 Includes Provention Bio's overallotment option: additional 750,000 shares.

11 PTC Therapeutics' overallotment option: additional 371,287 shares.

12 Translate Bio's overallotment option: additional 1.35M shares.

13 Turning Point Therapeutics' overallotment option: additional 675,000 shares.

14 Vaxart's overallotment option: additional 4M shares and/or common warrants to purchase up to an additional 4M shares.

15 Includes VBI Vaccines' overallotment option: additional 10.5M shares.

No Comments